ART for Prevention

Programas

ART for Prevention

People living with HIV are in favour of increasing access to existing forms of prevention and support the research of new prevention approaches to increase their reproductive health choices and to protect their partners.

Prevention strategies based on antiretrovirals (ARVs) are an established component of the global HIV response, including the prevention of vertical transmission and post-exposure prophylaxis (PEP). Recent trials have shown that ARVs could potentially also be used in other ways to prevent HIV, for example as pre-exposure prophylaxis (PrEP). However, there are many questions about the safety and effectiveness of such strategies. In addition there are serious questions about the ethical, practical and financial implications of making ARVs widely available for people who are not living with HIV.

GNP+ has participated in consultations and dialogues to advocate that people living with HIV are engaged in the development and implementation of ART for prevention strategies. In order to assess the impact of dramatically scaling up access to HIV testing and treatment on the lives of HIV-positive people, GNP+ is supporting the Swaziland Network of People Living with HIV to document the experiences and perspectives of people living with HIV and to assess the human rights implications.

SWANNEPHA and GNP+ present poster at Vancouver ART for prevention workshop

Jueves 21 de Junio de 2012 13:56

Preliminary findings from SWANNEPHA and GNP+'s research on Positive Health, Dignity and Prevention was presented at the 2nd International HIV Treatment as Prevention Workshop, held in Vancouver form 22 to 25 April 2012.

The Swaziland Network of People Living with HIV (SWANNEPHA) is playing a critical role in gathering evidence about the experiences of PLHIV within a national programme called Maximising ART for Better Health and Zero New Infections (MaxART). Led by the Ministry of Health, MaxART aims to scale up access to HIV testing and treatment in Swaziland.

Please click below to download the poster

pdf Documenting experiences of people living with HIV in the context of testing and treatment scale-up in Swaziland 5.79 Mb

News release: Call for human rights-based guidance on PrEP and ART as prevention

Lunes 18 de Julio de 2011 10:33

Amsterdam, 18 July 2011 - Preliminary results from two large studies have now shown that a daily antiretroviral tablet taken by people who do not have HIV reduces their risk of contracting HIV by up to 73%. The Partners PrEP trial involved 4758 HIV-discordant couples in Kenya and Uganda. The TDF2 trial involved 1219 men and women in Botswana.

The studies looked at both tenofovir or tenofovir plus emtricitabine (Truvada) and found that each, when taken in advance by the HIV-negative partner as a pre-exposure prophylaxis (PrEP), can prevent heterosexual transmission of HIV from men to women and from women to men.